We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Congenital Cytomegalovirus Infection Diagnosed Via Dried Blood Spots

By LabMedica International staff writers
Posted on 21 Aug 2019
Print article
Image: A newborn’s blood applied to a Guthrie Card for testing for various diseases including cytomegalovirus (Photo courtesy of NHS).
Image: A newborn’s blood applied to a Guthrie Card for testing for various diseases including cytomegalovirus (Photo courtesy of NHS).
Cytomegalovirus is the leading cause of congenital infection (cCMV) affecting up to 0.8% of newborns in high-income countries and is the most common cause of non-genetic deafness in childhood. A wide range of diseases diagnosed either at birth or in childhood, has been correlated to cCMV infection.

The diagnosis of cCMV infection can be achieved by the examination of salivary/urinary samples collected within the first 2–3 weeks of age as the results of newborn hearing screening program (NHSP). After this early period of life, it is possible to distinguish between congenital and acquired CMV infection just by examining the Dried Blood Spot (DBS) samples on the ‘Guthrie’ cards that are universally collected within three days from the birth.

Medical scientists at the Università degli Studi di Milano (Milan, Italy) collected DBS samples from children with a diagnosis of deafness that were retrieved from the regional neonatal screening center and tested for CMV between January 1, 2014, and December 31, 2018. DBS samples were processed by two separate in-house steps consisting of DNA extraction from the DBS samples by a heat-extraction-method, followed by amplification of a fragment of the CMV genome using a nested-polymerase chain reaction. The lower limit of detection of the CMV-DBS test was 400 CMV-DNA copies/mL.

The investigators reported that overall, 82 children were included with a median age of 3.4 months; (lower-upper quartiles: 2–5.3 months; males: 60.9%). Most of them (70.7%) presented bilateral hearing loss with a symmetrical pattern in 79.3% of the cases. Auditory Brainstem Responses (ABR) thresholds were ≥ 70 dB HL (severe/profound deafness) in 46.5% of children. Among all tested children, 6.1% resulted positive for cCMV. The rate of severe/profound deafness was statistically higher in children with cCMV infection.

The authors concluded that the addition of DBS-test to the NHSP allowed the identification, in their first months of life, of a cCMV infection in 6.1% of children who had failed NHS. The introduction of a targeted CMV screening strategy could help clinicians in the differential diagnosis and in the babies’ management. DBS samples can be considered a “universal newborns biobank”: their storage site and duration should be the subject of political decision-making. The study was published on July 22, 2019, in the journal BMC Infectious Diseases.

Related Links:
Università degli Studi di Milano

Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Mycoplasma Pneumoniae Virus Test
Mycoplasma Pneumoniae Virus Detection Kit
New
Bordetella Pertussis Molecular Assay
Alethia Pertussis

Print article

Channels

Molecular Diagnostics

view channel
Image: The Mirvie RNA platform predicts pregnancy complications months before they occur using a simple blood test (Photo courtesy of Mirvie)

RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms

Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.